The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Leah SherwoodMyelofibrosis | June 17, 2024
Dr. Rampal, of Memorial Sloan Kettering Cancer Center, discusses his abstract at the EHA 2024 Congress in Madrid, Spain.
View More
Patrick DalyMyelofibrosis | June 17, 2024
MPN depend on mutated JAK signaling, and targeting the mutations suppressed disease features and improved overall survival.
Patrick DalyMyelofibrosis | June 10, 2024
Pelabresib plus ruxolitinib improved spleen and symptom responses in JAKi-naïve patients with myelofibrosis.
Patrick DalyMyelofibrosis | June 7, 2024
Treatment with luspatercept improved transfusion burden and anemia across four cohorts of patients with myelofibrosis.
Leah SherwoodMyelofibrosis | May 22, 2024
Prefibrotic PMF is an MPN with distinct characteristics comprising histopathological, clinical, and biological parameters.
Prithviraj Bose, MDMyelofibrosis | May 2, 2024
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
Melissa BadamoMyelofibrosis | April 30, 2024
Momelotinib achieved higher rates of transfusion independence compared with ruxolitinib.
Melissa BadamoMyelofibrosis | April 30, 2024
Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with MF.
Melissa BadamoMyelofibrosis | April 29, 2024
Sotatercept monotherapy, and combined with ruxolitinib, is a safe and effective treatment for patients with PMF and anemia.
Melissa BadamoMyelofibrosis | April 4, 2024
The primary endpoint was overall best response after blast-reduction therapy.
Blood Cancers Today Staff WritersMyelofibrosis | April 1, 2024
Momelotinib and ruxolitinib improved bone marrow fibrosis, but changes were not associated with improved outcomes in MF.
Nicolaus Kröger, MDMyelofibrosis | March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
Patrick DalyMyelofibrosis | March 22, 2024
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.
Melissa BadamoMyelofibrosis | February 28, 2024
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with myelofibrosis.
Keightley AmenMyelofibrosis | February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Claire Harrison, MD, FRCP, FRCPathMyelofibrosis | February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Leah SherwoodMyelofibrosis | March 4, 2024
“Among the high-risk splicing mutations, SRSF2 has the worst prognostic role,” Dr. Braish and colleagues wrote.
Michael Grunwald, MDMyeloproliferative Neoplasms | December 14, 2023
The REVEAL study identified five risk factors, including leukocytosis, duration of time with PV, and more.
Patrick DalyMyelofibrosis | March 1, 2024
The treatment led to reduced hepcidin levels when used alone or in combination with ruxolitinib.
Editorial Board